Masitinib treatment for ALS led to 42% of patients in a clinical trial surviving five years, nearly double historical rates, ...
AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS Paris, April 20, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results